{"id":26074,"date":"2026-06-14T05:01:14","date_gmt":"2026-06-14T05:01:14","guid":{"rendered":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?p=26074"},"modified":"2026-06-14T05:04:19","modified_gmt":"2026-06-14T05:04:19","slug":"balancing-intellectual-property-rights-and-access-to-medicine","status":"publish","type":"post","link":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/","title":{"rendered":"Balancing Intellectual Property Rights And Access To Medicine"},"content":{"rendered":"\n<h2 id=\"h-introduction\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Introduction\"><\/span>Introduction<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Leading pharmaceutical companies play a crucial role in developing healthcare through the production of new drugs to battle various health problems. However, the patent system \u2013 a system that gives pharmaceutical companies the right to exclusively use IP \u2013 pushes up the price of drugs and denies care at a life-saving moment, especially to weaker countries. It thus clashes considerably with being the need to promote innovation by safeguarding intellectual property while assuring that crucial medicines for public health are accessible at affordable prices. In some cases, the monopoly enjoyed by pharmaceutical companies over their innovations is accompanied by a high price for medicine because of national patent laws and the TRIPS Agreement on Intellectual Property Rights.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #0c0c0c;color:#0c0c0c\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #0c0c0c;color:#0c0c0c\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Introduction\" >Introduction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Understanding_Intellectual_Property_Rights_in_Pharmaceuticals\" >Understanding Intellectual Property Rights in Pharmaceuticals<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Features_of_Pharmaceutical_Patents\" >Key Features of Pharmaceutical Patents<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Patents_and_Their_Role_in_Innovation\" >Patents and Their Role in Innovation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Importance_of_Patents_for_Pharmaceutical_Companies\" >Importance of Patents for Pharmaceutical Companies<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#TRIPS_Agreement_and_Its_Impact_on_Pharmaceutical_Patents\" >TRIPS Agreement and Its Impact on Pharmaceutical Patents<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Major_Features_of_the_TRIPS_Framework\" >Major Features of the TRIPS Framework<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#The_Monopoly_Power_of_Patents_and_Its_Implications_for_Pricing\" >The Monopoly Power of Patents and Its Implications for Pricing<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Effects_of_Patent_Monopoly_on_Drug_Pricing\" >Effects of Patent Monopoly on Drug Pricing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Summary_of_Key_Issues\" >Summary of Key Issues<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Challenges_to_Accessing_Affordable_Medicines\" >Challenges to Accessing Affordable Medicines<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Access_Challenges\" >Key Access Challenges<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#The_Impact_of_Patent_Protection_on_Drug_Prices\" >The Impact of Patent Protection on Drug Prices<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#How_Patents_Affect_Pricing\" >How Patents Affect Pricing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#The_Role_of_Pharmaceutical_Companies_in_Access_to_Medicines_4\" >The Role of Pharmaceutical Companies in Access to Medicines [4]<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Positive_and_Negative_Contributions\" >Positive and Negative Contributions<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Global_Inequalities_in_Access_Developed_vs_Developing_Nations\" >Global Inequalities in Access: Developed vs. Developing Nations<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Comparison_Between_Developed_and_Developing_Countries\" >Comparison Between Developed and Developing Countries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Major_Concerns_Arising_from_Global_Inequality\" >Major Concerns Arising from Global Inequality<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Compulsory_Licensing_as_a_Solution\" >Compulsory Licensing as a Solution<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Features_of_Compulsory_Licensing\" >Key Features of Compulsory Licensing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Benefits_of_Compulsory_Licensing\" >Benefits of Compulsory Licensing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Case_Studies_India_South_Africa_and_Brazil\" >Case Studies: India, South Africa, and Brazil<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#India\" >India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#South_Africa\" >South Africa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Brazil\" >Brazil<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Comparative_Overview_of_Compulsory_Licensing_Initiatives\" >Comparative Overview of Compulsory Licensing Initiatives<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Balancing_Innovation_and_Public_Health_The_Role_of_Generic_Medicines\" >Balancing Innovation and Public Health: The Role of Generic Medicines<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#The_Importance_of_Generic_Drug_Manufacturing\" >The Importance of Generic Drug Manufacturing<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Benefits_of_Generic_Medicines\" >Key Benefits of Generic Medicines<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Case_Study_Indias_Role_as_the_%E2%80%9CPharmacy_of_the_World%E2%80%9D\" >Case Study: India\u2019s Role as the \u201cPharmacy of the World\u201d<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Challenges_Faced_by_Generic_Drug_Manufacturers_Under_Current_IP_Laws\" >Challenges Faced by Generic Drug Manufacturers Under Current IP Laws<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Major_Challenges_Under_Current_IP_Regime\" >Major Challenges Under Current IP Regime<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Public_Health_Exceptions_in_Patent_Law\" >Public Health Exceptions in Patent Law<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Use_of_Patent_Exceptions_for_Public_Health_Purposes\" >Use of Patent Exceptions for Public Health Purposes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#The_Role_of_Governmental_Interventions_and_Policies\" >The Role of Governmental Interventions and Policies<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Policy_Tools_for_Access_to_Medicines\" >Policy Tools for Access to Medicines<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Recent_Legal_Battles_Over_Patent_Infringement_and_Policies\" >Recent Legal Battles Over Patent Infringement and Policies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Bayer_Corporation_v_Union_of_India_2012\" >Bayer Corporation v. Union of India (2012)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Legal_and_Ethical_Considerations\" >Legal and Ethical Considerations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Ethical_Concerns_in_Balancing_IP_and_Access_to_Medicines\" >Ethical Concerns in Balancing IP and Access to Medicines<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Ethical_Issues\" >Key Ethical Issues<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Human_Right_to_Health_vs_Corporate_Patent_Rights\" >Human Right to Health vs. Corporate Patent Rights<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Comparison_Human_Right_to_Health_and_Patent_Rights\" >Comparison: Human Right to Health and Patent Rights<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Legal_Frameworks_in_Different_Jurisdictions\" >Legal Frameworks in Different Jurisdictions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Comparative_Approach_to_Public_Health_and_IP_Rights\" >Comparative Approach to Public Health and IP Rights<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Conclusion\" >Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#Key_Takeaways\" >Key Takeaways<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n\n\n\n<p class=\"wp-block-paragraph\">It is during such emergencies that the pandemic of COVID-19 and the HIV\/AIDS epidemic have thrown light on the importance of flexible intellectual property regimes for granting access. With that, this essay is focused on discussing the trade-off between intellectual property rights and medical access regarding the function of generic medicines and other legal remedies, such as mandatory licensing.<\/p>\n\n\n\n<h2 id=\"h-understanding-intellectual-property-rights-in-pharmaceuticals\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Understanding_Intellectual_Property_Rights_in_Pharmaceuticals\"><\/span>Understanding Intellectual Property Rights in Pharmaceuticals<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Intellectual property (IP) rights are an essential element in the pharmaceutical industry. It protects and promotes innovation as well. For the pharmaceutical drug market, patents are a very crucial aspect because they give the pharmaceutical companies a monopoly, or in other words, the right to use their ideas exclusively for a specified period, which usually is 20 years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In turn, exclusive rights thus enable the patent holder to have a drug&#8217;s monopolistic right on production and pricing since such rights do not allow competitors to manufacture or sell it without the patent holder&#8217;s permission. While patents spur innovation by promoting what often requires immense sums of money in research and development (R&amp;D), patents also make it harder for people to receive access to low-cost drugs, especially in developing countries where patented drugs may be prohibitively priced [1].<\/p>\n\n\n\n<h3 id=\"h-key-features-of-pharmaceutical-patents\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Features_of_Pharmaceutical_Patents\"><\/span>Key Features of Pharmaceutical Patents<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td>Patent Protection<\/td><td>Provides exclusive rights to pharmaceutical companies over their inventions.<\/td><\/tr><tr><td>Duration<\/td><td>Usually granted for a period of 20 years.<\/td><\/tr><tr><td>Monopoly Rights<\/td><td>Prevents competitors from manufacturing or selling the patented drug without authorisation.<\/td><\/tr><tr><td>R&amp;D Incentive<\/td><td>Encourages investment in costly research and development activities.<\/td><\/tr><tr><td>Access Concerns<\/td><td>Can limit the availability of affordable medicines, especially in developing countries.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-patents-and-their-role-in-innovation\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Patents_and_Their_Role_in_Innovation\"><\/span>Patents and Their Role in Innovation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patents are crucial to innovation in pharmaceuticals. The creation of a new drug involves several years of research, clinical trials, and clearance processes that are undeniably capital-intensive. Pharmaceutical companies can recover their investment by charging sky-high prices for their patented drugs because of the temporary exclusivity patents give them. The patent monopoly period is critically essential to provoke more research, as, in the absence of patent protection, companies could not be economically motivated to take the risk of investing in highly costly R&amp;D ventures. Although patents inspire pharmaceutical research, simultaneously, they also raise the price of drugs that prevents many individuals from acquiring their life-saving treatment.<\/p>\n\n\n\n<h3 id=\"h-importance-of-patents-for-pharmaceutical-companies\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Importance_of_Patents_for_Pharmaceutical_Companies\"><\/span>Importance of Patents for Pharmaceutical Companies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Encourage innovation and drug discovery.<\/li>\n\n\n\n<li>Provide temporary market exclusivity.<\/li>\n\n\n\n<li>Help recover substantial R&amp;D investments.<\/li>\n\n\n\n<li>Support long-term pharmaceutical research projects.<\/li>\n\n\n\n<li>Create economic incentives for developing new treatments.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-trips-agreement-and-its-impact-on-pharmaceutical-patents\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TRIPS_Agreement_and_Its_Impact_on_Pharmaceutical_Patents\"><\/span>TRIPS Agreement and Its Impact on Pharmaceutical Patents<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The World Trade Organisation enforces the TRIPS Agreement, which established minimum requirements for the protection of IP rights, including pharmaceutical patents and the harmonisation of patent laws throughout the world. TRIPS has required WTO members to provide 20 years of patent protection but has severely impacted the availability of healthcare across the globe. While pushing pharmaceutical inventions worldwide, it was also criticised for supposedly limiting access to relatively affordable drugs, especially in less developed nations [2]. However, as the 2001 Doha Declaration set forth, provisions like compulsory licensing under TRIPS allow governments to manufacture generic versions of copyrighted medicines in cases of public health emergency [3].<\/p>\n\n\n\n<h3 id=\"h-major-features-of-the-trips-framework\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Major_Features_of_the_TRIPS_Framework\"><\/span>Major Features of the TRIPS Framework<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>TRIPS Provision<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td>Minimum Patent Standards<\/td><td>Requires WTO members to provide patent protection.<\/td><\/tr><tr><td>20-Year Patent Term<\/td><td>Ensures long-term exclusivity for patent holders.<\/td><\/tr><tr><td>Global Harmonization<\/td><td>Aligns patent laws across member countries.<\/td><\/tr><tr><td>Compulsory Licensing<\/td><td>Permits production of generic medicines during public health emergencies.<\/td><\/tr><tr><td>Doha Declaration<\/td><td>Affirms the right of governments to protect public health.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-the-monopoly-power-of-patents-and-its-implications-for-pricing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Monopoly_Power_of_Patents_and_Its_Implications_for_Pricing\"><\/span>The Monopoly Power of Patents and Its Implications for Pricing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">During the period of the patent, pharmaceutical companies enjoy monopolistic control over both the manufacture and pricing of pharmaceuticals. Because businesses can set prices that incorporate significant investments in marketing and research and production costs, exclusivity normally results in higher prices. These high prices severely impair access to needed drugs, especially in low-income countries \u2013 even when they could be deemed acceptable as a means to recoup R&amp;D costs. Companies also frequently engage in &#8220;evergreening&#8221;, with minor tweaks to drugs to keep patents longer and further prolong the arrival of reasonably priced generics, and thus further entrench inequities in global health. This seems to be the ongoing legal and moral dilemma about finding a balance between patent rights and the demand for low-price accessibility.<\/p>\n\n\n\n<h3 id=\"h-effects-of-patent-monopoly-on-drug-pricing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Effects_of_Patent_Monopoly_on_Drug_Pricing\"><\/span>Effects of Patent Monopoly on Drug Pricing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Allows pharmaceutical companies to control drug prices.<\/li>\n\n\n\n<li>Limits competition during the patent term.<\/li>\n\n\n\n<li>Increases the cost of life-saving medicines.<\/li>\n\n\n\n<li>Reduces affordability in low-income and developing countries.<\/li>\n\n\n\n<li>Encourages practices such as evergreening to extend exclusivity.<\/li>\n\n\n\n<li>Creates ongoing debates regarding public health and intellectual property rights.<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-summary-of-key-issues\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary_of_Key_Issues\"><\/span>Summary of Key Issues<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Issue<\/th><th>Effect on Public Health<\/th><\/tr><\/thead><tbody><tr><td>Patent Exclusivity<\/td><td>Promotes innovation but restricts competition.<\/td><\/tr><tr><td>High Drug Prices<\/td><td>Reduces access to essential medicines.<\/td><\/tr><tr><td>TRIPS Compliance<\/td><td>Strengthens global IP protection.<\/td><\/tr><tr><td>Compulsory Licensing<\/td><td>Improves access during health emergencies.<\/td><\/tr><tr><td>Evergreening<\/td><td>Delays entry of affordable generic medicines.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-challenges-to-accessing-affordable-medicines\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Challenges_to_Accessing_Affordable_Medicines\"><\/span>Challenges to Accessing Affordable Medicines<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">One of the main concerns in the global health agenda over access to affordable medicines is the right to patents by pharmaceutical companies. With the existence of patents, companies can charge even very high prices for their medicines simply to recoup the investment in R&amp;D. Additionally, they will have the exclusive right to produce and sell those medicines for a specified period. This, hence, leaves low-income people at a total disadvantage, especially in developing countries, where out-of-pocket costs are high and the healthcare sector is underfunded.<\/p>\n\n\n\n<h3 id=\"h-key-access-challenges\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Access_Challenges\"><\/span>Key Access Challenges<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patent-based exclusivity in medicine production and distribution.<\/li>\n\n\n\n<li>High medicine prices aimed at recovering R&amp;D investments.<\/li>\n\n\n\n<li>Limited affordability for low-income populations.<\/li>\n\n\n\n<li>High out-of-pocket healthcare expenditures.<\/li>\n\n\n\n<li>Underfunded healthcare systems in developing countries.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-the-impact-of-patent-protection-on-drug-prices\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Impact_of_Patent_Protection_on_Drug_Prices\"><\/span>The Impact of Patent Protection on Drug Prices<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In large measure, patent protection inflates drug prices. The lack of generic competition throughout the patent period gives the patent-owning pharmaceutical company near-monopoly over the drug. Such prices are often set well above cost because of this. Millions of patients are barred from taking medicines that could save their lives, for example, cancer treatments or antiretrovirals for HIV, even though patents are justified on the rationale that they enable companies to recover their investments and induce new drugs.<\/p>\n\n\n\n<h3 id=\"h-how-patents-affect-pricing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Patents_Affect_Pricing\"><\/span>How Patents Affect Pricing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patent Protection Feature<\/th><th>Impact on Drug Prices<\/th><\/tr><\/thead><tbody><tr><td>Exclusive Rights<\/td><td>Patent owners control production and sales.<\/td><\/tr><tr><td>Limited Competition<\/td><td>Generic manufacturers cannot enter the market.<\/td><\/tr><tr><td>Market Dominance<\/td><td>Companies gain near-monopoly status.<\/td><\/tr><tr><td>Higher Pricing Power<\/td><td>Drug prices are often set significantly above production costs.<\/td><\/tr><tr><td>Patient Access Barriers<\/td><td>Essential medicines become unaffordable for many patients.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-the-role-of-pharmaceutical-companies-in-access-to-medicines-4\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Role_of_Pharmaceutical_Companies_in_Access_to_Medicines_4\"><\/span>The Role of Pharmaceutical Companies in Access to Medicines [4]<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Because of their potential to either assist or hinder affordability, pharmaceutical companies have a great role in whether it is easy or not to access medicines through their pricing mechanisms and rules on patents. Some companies have made voluntary licensing agreements or have mounted international campaigns to better increase access to pharmaceuticals in the less developed countries. However, most focus on maximising profit, and many times, this leads to low-income communities accessing fewer innovative drugs.<\/p>\n\n\n\n<h3 id=\"h-positive-and-negative-contributions\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Positive_and_Negative_Contributions\"><\/span>Positive and Negative Contributions<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Positive Actions<\/th><th>Challenges<\/th><\/tr><\/thead><tbody><tr><td>Voluntary licensing agreements<\/td><td>Profit maximisation strategies<\/td><\/tr><tr><td>International access campaigns<\/td><td>High pricing structures<\/td><\/tr><tr><td>Expanded availability in less developed countries<\/td><td>Limited access to innovative medicines for low-income communities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-global-inequalities-in-access-developed-vs-developing-nations\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Global_Inequalities_in_Access_Developed_vs_Developing_Nations\"><\/span>Global Inequalities in Access: Developed vs. Developing Nations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Developed countries have better health care structures, covered by various insurance policies, and have better negotiating positions to come out with easy access to patented drugs in most instances.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Developing countries experience serious medicine price problems; government funding is also scarce; and their health care systems and related infrastructures are weak compared with those of developed countries. This is the reason for significant gaps in the area of access. This raises questions about how unevenly necessary drugs are being distributed and, therefore, how much international co-operation and legal changes are badly needed to cope with this problem.<\/p>\n\n\n\n<h3 id=\"h-comparison-between-developed-and-developing-countries\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Comparison_Between_Developed_and_Developing_Countries\"><\/span>Comparison Between Developed and Developing Countries<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Developed Countries<\/th><th>Developing Countries<\/th><\/tr><\/thead><tbody><tr><td>Healthcare Infrastructure<\/td><td>Well-developed<\/td><td>Often underdeveloped<\/td><\/tr><tr><td>Insurance Coverage<\/td><td>Widespread<\/td><td>Limited<\/td><\/tr><tr><td>Government Funding<\/td><td>Relatively strong<\/td><td>Often scarce<\/td><\/tr><tr><td>Access to Patented Medicines<\/td><td>Generally better<\/td><td>Frequently restricted by high costs<\/td><\/tr><tr><td>Negotiating Power<\/td><td>Stronger<\/td><td>Weaker<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-major-concerns-arising-from-global-inequality\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Major_Concerns_Arising_from_Global_Inequality\"><\/span>Major Concerns Arising from Global Inequality<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Uneven distribution of essential medicines.<\/li>\n\n\n\n<li>Limited access to life-saving treatments.<\/li>\n\n\n\n<li>Weak healthcare infrastructure in poorer nations.<\/li>\n\n\n\n<li>Need for stronger international cooperation.<\/li>\n\n\n\n<li>Requirement for legal and policy reforms.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-compulsory-licensing-as-a-solution\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Compulsory_Licensing_as_a_Solution\"><\/span>Compulsory Licensing as a Solution<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Compulsory licences can be issued by governments to sanction generic versions of copyrighted medicines even without the consent of the patent holders, through a legal process known as compulsory licensing. It usually happens when there is an exceptional public health emergency. Compulsory Licensing, enacted under the TRIPS Agreement of the WTO, ensures access to a life-saving treatment at affordable prices and balances the rights of intellectual property with public health. Governments can license firms under specific conditions, for example, in cases of national crises or anticompetitive behaviour. This allows local producers to manufacture drugs locally, and because the latter are not branded, the prices will be cheaper and accessible.<\/p>\n\n\n\n<h3 id=\"h-key-features-of-compulsory-licensing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Features_of_Compulsory_Licensing\"><\/span>Key Features of Compulsory Licensing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Allows production of generic versions of patented medicines.<\/li>\n\n\n\n<li>Can be implemented without patent-holder consent.<\/li>\n\n\n\n<li>Generally used during public health emergencies.<\/li>\n\n\n\n<li>Recognised under the TRIPS Agreement of the WTO.<\/li>\n\n\n\n<li>Balances intellectual property rights and public health needs.<\/li>\n\n\n\n<li>Encourages affordable access to life-saving medicines.<\/li>\n\n\n\n<li>Supports local manufacturing and reduces medicine costs.<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-benefits-of-compulsory-licensing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Benefits_of_Compulsory_Licensing\"><\/span>Benefits of Compulsory Licensing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Benefit<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Generic Drug Production<\/td><td>Increased availability of medicines<\/td><\/tr><tr><td>Lower Prices<\/td><td>Improved affordability<\/td><\/tr><tr><td>Local Manufacturing<\/td><td>Enhanced domestic supply capacity<\/td><\/tr><tr><td>Public Health Protection<\/td><td>Better access during health emergencies<\/td><\/tr><tr><td>Balanced Legal Framework<\/td><td>Protects both innovation and public health interests<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-case-studies-india-south-africa-and-brazil\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Case_Studies_India_South_Africa_and_Brazil\"><\/span>Case Studies: India, South Africa, and Brazil<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Several countries have effectively used compulsory licensing to combat public health challenges:<\/p>\n\n\n\n<h3 id=\"h-india\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"India\"><\/span>India<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For enhancing accessibility to reasonably priced drugs, India is known to make strategic usage of compulsory licensing [5]. For the first time, India implemented mandatory licensing in 2012 for the Bayer cancer drug Nexavar, which is sorafenib. The Indian government cleared Natco Pharma, a local manufacturer, for making the generic version and brought the price down by more than 90 per cent. Bayer quoted it around $5,600 for a month. The generic alternative would have cost around $175. This ruling set an important precedent in the use of compulsory licensing in a public health emergency and increased dramatically a patient&#8217;s access to life-saving treatment for cancer in India [6].<\/p>\n\n\n\n<h3 id=\"h-south-africa\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"South_Africa\"><\/span>South Africa<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">South Africa had to come to compulsory licensing in the midst of the HIV\/AIDS epidemic when the cost for antiretroviral (ARV) treatments, which many could not afford anyway, was just too high. Government pressure and a licence would force the pharmaceutical companies to cut down the exorbitant prices of the ARVs by manyfold. In effect, it helped citizens get access to drugs that could save their lives in time and help South Africa combat the outbreak of HIV infections [7].<\/p>\n\n\n\n<h3 id=\"h-brazil\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Brazil\"><\/span>Brazil<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brazil also used its compulsory licensing in the early 2000s to produce low-cost HIV\/AIDS drugs. Compulsory licensing was used on government patents for expensive ARVs, such that low-end local companies were able to manufacture the generic versions at much more affordable prices. This cut down the treatment cost significantly and made it easier for the country to effectively deal with the HIV\/AIDS challenge [8].<\/p>\n\n\n\n<h3 id=\"h-comparative-overview-of-compulsory-licensing-initiatives\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Comparative_Overview_of_Compulsory_Licensing_Initiatives\"><\/span>Comparative Overview of Compulsory Licensing Initiatives<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Country<\/th><th>Health Challenge<\/th><th>Key Intervention<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>India<\/td><td>Cancer Treatment Accessibility<\/td><td>Compulsory licence for Nexavar (sorafenib)<\/td><td>Price reduced by over 90%, improved patient access<\/td><\/tr><tr><td>South Africa<\/td><td>HIV\/AIDS Epidemic<\/td><td>Compulsory licensing and government pressure on ARV pricing<\/td><td>Affordable access to life-saving medicines<\/td><\/tr><tr><td>Brazil<\/td><td>HIV\/AIDS Management<\/td><td>Compulsory licensing of ARV patents<\/td><td>Reduced treatment costs and wider access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-balancing-innovation-and-public-health-the-role-of-generic-medicines\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Balancing_Innovation_and_Public_Health_The_Role_of_Generic_Medicines\"><\/span>Balancing Innovation and Public Health: The Role of Generic Medicines<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Generic drugs, providing affordable alternatives to patented drugs, are vital in maintaining a balance between public health and pharmaceutical innovation. Generic drugs deliver life-saving therapies in the low-income regions when the patents have expired. Global health equity will require generics, even though patents held at the full extension permitted under current law and draconian IP rules present obstacles.<\/p>\n\n\n\n<h3 id=\"h-the-importance-of-generic-drug-manufacturing\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Importance_of_Generic_Drug_Manufacturing\"><\/span>The Importance of Generic Drug Manufacturing<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Generic drug manufacturing plays a very important role in bridging that gap between innovation and public health. With the expiry of a drug&#8217;s patent, generic manufacturers can create comparable drugs at a fraction of the price, thereby increasing access to needed therapies, especially in low-income countries. It is also helping meet public health needs by making affordable alternatives available to expensive proprietary medications for life-saving therapies, such as insulin, cancer therapies, and antiretrovirals in HIV\/AIDS. Generics are critical in helping balance the profit-driven innovation paradigm of the pharmaceutical business with a more general goal of global health equity through competitive pricing.<\/p>\n\n\n\n<h4 id=\"h-key-benefits-of-generic-medicines\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Benefits_of_Generic_Medicines\"><\/span>Key Benefits of Generic Medicines<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Lower treatment costs for patients.<\/li>\n\n\n\n<li>Increased access to essential medicines.<\/li>\n\n\n\n<li>Enhanced public health outcomes.<\/li>\n\n\n\n<li>Greater market competition and competitive pricing.<\/li>\n\n\n\n<li>Support for global health equity initiatives.<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-case-study-india-s-role-as-the-pharmacy-of-the-world\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Case_Study_Indias_Role_as_the_%E2%80%9CPharmacy_of_the_World%E2%80%9D\"><\/span>Case Study: India\u2019s Role as the \u201cPharmacy of the World\u201d<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Due to the status sometimes accorded to India as the &#8220;Pharmacy of the World&#8221;, it now finds itself on the front line in producing generic drugs. The country exports high-quality and reasonably priced generic medications to over 200 nations. Indian generics have played a significant role globally in health initiatives, especially in fighting HIV\/AIDS by granting access to affordable antiretrovirals for millions of people in impoverished nations. It became very flexible regarding patent rules, and the Indian pharmaceutical industry was, in fact, flourishing and is using compulsory licensing too. Based on this, affordable medicines were made accessible to people from all parts of the globe [9].<\/p>\n\n\n\n<h3 id=\"h-challenges-faced-by-generic-drug-manufacturers-under-current-ip-laws\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Challenges_Faced_by_Generic_Drug_Manufacturers_Under_Current_IP_Laws\"><\/span>Challenges Faced by Generic Drug Manufacturers Under Current IP Laws<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">There are a number of hurdles that block generic drug producers under the current intellectual property regimes. The patent protections, as offered by TRIPS-compliant standards, keep the monopolies of the pharmaceutical corporations in business by delaying the generation&#8217;s entry into the market. The other tactics \u2013 never-ending evergreening \u2013 minimal changes done on a drug&#8217;s patent to extend the life of the drug [10]. These issues also fall harder in developing and low-income nations, as they hinder on-time access to reasonably priced generics.<\/p>\n\n\n\n<h4 id=\"h-major-challenges-under-current-ip-regime\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Major_Challenges_Under_Current_IP_Regime\"><\/span>Major Challenges Under Current IP Regime<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extended patent monopolies.<\/li>\n\n\n\n<li>Delayed market entry of generic medicines.<\/li>\n\n\n\n<li>Evergreening practices extending patent life.<\/li>\n\n\n\n<li>Reduced affordability in developing countries.<\/li>\n\n\n\n<li>Barriers to timely access to essential treatments.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-public-health-exceptions-in-patent-law\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Public_Health_Exceptions_in_Patent_Law\"><\/span>Public Health Exceptions in Patent Law<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patents on public health exceptions allow governments to promote the availability of essential drugs as opposed to strict enforcement of patents. Mechanisms such as compulsory licensing enable countries to make affordably available generics in times of health crises. The tug and pull of public health and intellectual property rights continue, the current court cases attesting.<\/p>\n\n\n\n<h3 id=\"h-use-of-patent-exceptions-for-public-health-purposes\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Use_of_Patent_Exceptions_for_Public_Health_Purposes\"><\/span>Use of Patent Exceptions for Public Health Purposes<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Exceptions to public health-related patent law ensure that a need for affordable medicines is prioritised above strict protection of intellectual property rights. In order to make available essential medicines to many people, especially during public health emergencies, several governments allow exceptions to, or restrictions on, patent rights. These provisions guarantee that nations can respond to medical emergencies in a timely manner by allowing governments to bypass patent protections on lifesaving medicines, thereby providing at-risk populations with the therapies they need.<\/p>\n\n\n\n<h3 id=\"h-the-role-of-governmental-interventions-and-policies\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Role_of_Governmental_Interventions_and_Policies\"><\/span>The Role of Governmental Interventions and Policies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Effective use of public health exceptions relies on government action. The two policies that allow a country to manufacture or obtain generic copies of patented medications without infringing on patent rights are compulsory licensing and parallel importation. Countries, for example, Brazil and India, have proved that it is possible to advance public health interests in respect of the challenges of patent law through political pressure to successfully implement such measures in expanding access to antiretroviral drugs for HIV\/AIDS.<\/p>\n\n\n\n<h4 id=\"h-policy-tools-for-access-to-medicines\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Policy_Tools_for_Access_to_Medicines\"><\/span>Policy Tools for Access to Medicines<span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Policy Tool<\/th><th>Purpose<\/th><\/tr><\/thead><tbody><tr><td>Compulsory Licensing<\/td><td>Allows production of generic versions of patented medicines during public health needs.<\/td><\/tr><tr><td>Parallel Importation<\/td><td>Permits import of patented medicines from markets where they are sold at lower prices.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-recent-legal-battles-over-patent-infringement-and-policies\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Legal_Battles_Over_Patent_Infringement_and_Policies\"><\/span>Recent Legal Battles Over Patent Infringement and Policies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Recent court cases highlight the conflict between public health and patent protection. Instances such as the cases in which pharmaceutical corporations objected to governments&#8217; rights to make use of compulsory licensing underscore the continuing battle to balance such pressing needs for affordable medication with incentives for innovation. These jurisprudential setbacks underscore the importance of maintaining balance in overtly draconian legal regimes that safeguard the rights of patent holders but also allow for certain exemptions on public health grounds and thus, globally, would tend towards a balanced approach to intellectual property in health.<\/p>\n\n\n\n<h3 id=\"h-bayer-corporation-v-union-of-india-2012\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_Corporation_v_Union_of_India_2012\"><\/span>Bayer Corporation v. Union of India (2012)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">One such case is Bayer Corporation v. Union of India (2012) [11], where India granted its first compulsory licence for Bayer&#8217;s cancer medicine, Nexavar, or sorafenib. A large number of patients could not afford the said treatment, as Bayer was charging an astronomic price for it. Acting on this, the Indian Patent Office handed down a verdict, claiming that the drug was unavailable at a reasonable price, and granted a generic manufacturer permission to manufacture it at a significantly lower cost.<\/p>\n\n\n\n<h2 id=\"h-legal-and-ethical-considerations\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Legal_and_Ethical_Considerations\"><\/span>Legal and Ethical Considerations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ethical issues pertaining to the monetarisation of profits above public health arise since there is a balance in accessing medication and that of intellectual property rights. Conflicts, on the other hand, lie between the human right to health and corporate patent rights. Legal systems are different; in some countries, flexible intellectual property laws are tolerated so that the access to cheap medicines can be extended, especially when emergency situations prevail in the medical profession.<\/p>\n\n\n\n<h2 id=\"h-ethical-concerns-in-balancing-ip-and-access-to-medicines\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ethical_Concerns_in_Balancing_IP_and_Access_to_Medicines\"><\/span>Ethical Concerns in Balancing IP and Access to Medicines<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Balancing access to necessary medications with intellectual property rights thus raises serious ethical questions. Pharmaceutical firms argue on one hand that strong patent protections are necessary to recover R&amp;D expenses and to encourage innovation. But for low-income groups \u2013 especially in developing countries \u2013 these patented medicines sometimes remain inaccessible due to their costs. This raises an ethical question: Would financial incentives outweigh the demand for affordable drugs globally?<\/p>\n\n\n\n<h3 id=\"h-key-ethical-issues\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Ethical_Issues\"><\/span>Key Ethical Issues<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Balancing pharmaceutical innovation with affordable healthcare.<\/li>\n\n\n\n<li>Ensuring access to life-saving medicines for low-income populations.<\/li>\n\n\n\n<li>Reconciling intellectual property rights with public health needs.<\/li>\n\n\n\n<li>Addressing disparities in access between developed and developing countries.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-human-right-to-health-vs-corporate-patent-rights\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Human_Right_to_Health_vs_Corporate_Patent_Rights\"><\/span>Human Right to Health vs. Corporate Patent Rights<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The human right to health, as articulated in the Universal Declaration of Human Rights [12] and other international treaties, obliges everyone to a basic form of medical treatment available to them, including medicines. Such a fundamental right often comes into conflict with the corporate patent rights, as the latter give precedence to the financial interests of pharmaceutical corporations. This is because while patents become too high in profile for public health goals to be neglected, making patents too high in profile undermines the attainment of public health objectives because unequal access to life-saving therapies may be realised.<\/p>\n\n\n\n<h3 id=\"h-comparison-human-right-to-health-and-patent-rights\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Comparison_Human_Right_to_Health_and_Patent_Rights\"><\/span>Comparison: Human Right to Health and Patent Rights<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Human Right to Health<\/th><th>Corporate Patent Rights<\/th><\/tr><\/thead><tbody><tr><td>Primary Objective<\/td><td>Access to healthcare and medicines<\/td><td>Protection of innovation and investment<\/td><\/tr><tr><td>Beneficiaries<\/td><td>General public and patients<\/td><td>Pharmaceutical companies and inventors<\/td><\/tr><tr><td>Key Concern<\/td><td>Availability and affordability of medicines<\/td><td>Recovery of R&amp;D costs and profit incentives<\/td><\/tr><tr><td>Potential Conflict<\/td><td>Limited access to treatment<\/td><td>Exclusive market control through patents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-legal-frameworks-in-different-jurisdictions\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Legal_Frameworks_in_Different_Jurisdictions\"><\/span>Legal Frameworks in Different Jurisdictions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The balance between public health and IP rights has been struck much differently by various countries in a completely different legal stance. For example, flexible intellectual property laws of India, which incorporate mandatory licensing, allowed the production of reasonably priced generic medicines. On the other hand, the US still maintains stronger patent protections, where patents often delay the entry of generics. A comparative study has shown that both Brazil and South Africa, countries with lenient rules regarding intellectual properties, have utilised the legal framework to gain access to such medicines which are greatly needed during public health emergencies.<\/p>\n\n\n\n<h3 id=\"h-comparative-approach-to-public-health-and-ip-rights\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Comparative_Approach_to_Public_Health_and_IP_Rights\"><\/span>Comparative Approach to Public Health and IP Rights<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Country<\/th><th>Approach to IP Rights<\/th><th>Impact on Access to Medicines<\/th><\/tr><\/thead><tbody><tr><td>India<\/td><td>Flexible IP laws with mandatory licensing<\/td><td>Encourages affordable generic medicines<\/td><\/tr><tr><td>United States<\/td><td>Strong patent protections<\/td><td>May delay generic market entry<\/td><\/tr><tr><td>Brazil<\/td><td>More flexible public health-oriented framework<\/td><td>Improves access during health emergencies<\/td><\/tr><tr><td>South Africa<\/td><td>Lenient IP regulations in certain contexts<\/td><td>Facilitates access to essential medicines<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This situation underlines an ongoing ethical and legal debate over how to ensure intellectual property rights do not violate the universal right to health.<\/p>\n\n\n\n<h2 id=\"h-conclusion\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Continued concerns over global access to medicines and intellectual property rights, particularly concerning life-saving therapies, also continue to pressure pharmaceutical innovation. &#8220;On the one hand, patent protection is essential for promoting pharmaceutical innovation. On the other hand, it may create monopolies that increase access prices to medications for disadvantaged populations.&#8221; Such salient topics are the ethical dilemma between the human right to health and corporate patent rights, generics in guaranteeing access, and legislation in the guise of mandated licensing. Elastic IP frameworks do indeed augment the pro-health policies&#8217; benefits in Brazil, South Africa, and India; yet, there still exist quite disparate access inequities regardless of where on this earth one may stand, in the distinction often made between developed and developing countries.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To address these problems, legal reforms are needed, including promoting compulsory licensing during public health emergencies and relaxing patents by discouraging activities such as evergreening that unduly extend patent monopolies. Prior to national and international policy changes, fair access to essential medicines must be recognised as a prior priority. Only when a balance has been struck between the demand for low-cost healthcare in the global sphere and innovation incentives in such a way that intellectual property laws do not become obstacles to the realisation of this fundamental right to health will it be possible to live together in peace with IP rights and public health.<\/p>\n\n\n\n<h3 id=\"h-key-takeaways\" class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Takeaways\"><\/span>Key Takeaways<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patent protection remains essential for pharmaceutical innovation.<\/li>\n\n\n\n<li>High medicine prices can restrict access for vulnerable populations.<\/li>\n\n\n\n<li>Generic medicines play a critical role in expanding healthcare access.<\/li>\n\n\n\n<li>Compulsory licensing can be an effective tool during public health emergencies.<\/li>\n\n\n\n<li>Countries such as India, Brazil, and South Africa demonstrate the benefits of flexible IP frameworks.<\/li>\n\n\n\n<li>Future legal reforms should focus on balancing innovation incentives with the universal right to health.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Endnotes:<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Outterson, Kevin, &#8220;Pharmaceutical Arbitrage: Balancing Access and Innovation in International Drug Markets.&#8221; 5 Yale Journal of Health Policy, Law, and Ethics 193 (2005).<\/li>\n\n\n\n<li>Sell, Susan K., &#8220;TRIPS and the Access to Medicines Campaign.&#8221; 20 Wisconsin International Law Journal 481 (2002).<\/li>\n\n\n\n<li>Correa, Carlos M., &#8220;Implications of the Doha Declaration on the TRIPS Agreement and Public Health.&#8221; World Health Organization (2002).<br>URL: https:\/\/apps.who.int\/iris\/handle\/10665\/68990<\/li>\n\n\n\n<li>Moon, Suerie. &#8220;Powerful Ideas: The Global Politics of Pharmaceutical Monopoly.&#8221; 44 Journal of Health Politics, Policy and Law 251 (2019).<\/li>\n\n\n\n<li>R. Raghavan, &#8220;India Grants First Compulsory Licence to Generic Drug Manufacturer&#8221;, 30 Nature Biotechnology 321 (2012).<\/li>\n\n\n\n<li>Dhar, Biswajit, and K.M. Gopakumar, &#8220;Compulsory Licensing in India: The Bayer-Natco Case.&#8221; 18 The Journal of Intellectual Property Rights 132 (2013).<\/li>\n\n\n\n<li>Heywood, Mark. &#8220;South Africa\u2019s Treatment Action Campaign: Combining Law and Social Mobilisation to Realise the Right to Health.&#8221; 1 Journal of Human Rights Practice 14 (2009).<\/li>\n\n\n\n<li>Flynn, Matthew, &#8220;Brazilian Pharmaceutical Diplomacy: Social Democratic Principles versus Soft Power Interests.&#8221; 43 International Journal of Health Services 67 (2013).<\/li>\n\n\n\n<li>Kumar, Anil, &#8220;India as the Pharmacy of the World: The Challenges and Opportunities.&#8221; 77 Indian Journal of Pharmaceutical Sciences 275 (2015).<\/li>\n\n\n\n<li>Sell, Susan K., &#8220;TRIPS and the Access to Medicines Campaign.&#8221; 20 Wisconsin International Law Journal 481 (2002).<\/li>\n\n\n\n<li>Bayer Corporation v. Union of India, (2012) IPD 103.<\/li>\n\n\n\n<li>Universal Declaration of Human Rights, G.A. Res. 217 A (III), U.N. Doc. A\/810 at 71 (1948).<br>URL: https:\/\/www.un.org\/en\/about-us\/universal-declaration-of-human-rights<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-yoast-seo-related-links yoast-seo-related-links\">\n<li><a href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/patent-wars-in-the-pharma-sector-compulsory-licensing-and-public-interest\/\">Patent Wars in the Pharma Sector: Compulsory Licensing and Public Interest<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/penal-provisions-under-the-patents-act-1970-an-in-depth-examination\/\">Penal Provisions Under the Patents Act, 1970: An In-Depth Examination<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/policing-patents-understanding-the-limited-role-of-law-enforcement-under-the-patents-act-1970\/\">Policing Patents: Understanding the Limited Role of Law Enforcement under the Patents Act, 1970<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/patent-protection-india\/\">Patent Protection India<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/is-patent-linkage-necessity-or-potential-disaster-for-pharma-industry\/\">Is Patent Linkage A Necessity Or A Potential Disaster For Pharma Industry<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Introduction Leading pharmaceutical companies play a crucial role in developing healthcare through the production of new drugs to battle various health problems. However, the patent system \u2013 a system that gives pharmaceutical companies the right to exclusively use IP \u2013 pushes up the price of drugs and denies care at a life-saving moment, especially to<\/p>\n","protected":false},"author":1593,"featured_media":26088,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"two_page_speed":[],"_jetpack_memberships_contains_paid_content":false,"_joinchat":[],"footnotes":""},"categories":[21],"tags":[5149],"class_list":["post-26074","post","type-post","status-publish","format-standard","has-post-thumbnail","category-intellectual-property","tag-intellectual-property"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Balancing Intellectual Property Rights And Access To Medicine - Legal Service India - Articles<\/title>\n<meta name=\"description\" content=\"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Balancing Intellectual Property Rights And Access To Medicine\" \/>\n<meta property=\"og:description\" content=\"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Legal Service India - Articles\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/legalservicesind\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-14T05:01:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-14T05:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Swatikumari022\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@legalserviceind\" \/>\n<meta name=\"twitter:site\" content=\"@legalserviceind\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Swatikumari022\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/\"},\"author\":{\"name\":\"Swatikumari022\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/person\\\/b2a982e671155e9713fde14405ffa316\"},\"headline\":\"Balancing Intellectual Property Rights And Access To Medicine\",\"datePublished\":\"2026-06-14T05:01:14+00:00\",\"dateModified\":\"2026-06-14T05:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/\"},\"wordCount\":4059,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp\",\"keywords\":[\"Intellectual Property\"],\"articleSection\":[\"Intellectual Property\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/\",\"name\":\"Balancing Intellectual Property Rights And Access To Medicine - Legal Service India - Articles\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp\",\"datePublished\":\"2026-06-14T05:01:14+00:00\",\"dateModified\":\"2026-06-14T05:04:19+00:00\",\"description\":\"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp\",\"contentUrl\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp\",\"width\":1536,\"height\":1024,\"caption\":\"Intellectual Property Rights and Access to Medicines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/balancing-intellectual-property-rights-and-access-to-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellectual Property > Balancing Intellectual Property Rights And Access To Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#website\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\",\"name\":\"Legal Service India - Law Articles\",\"description\":\"Legal Service India - Law Article Directory is the oldest in India since 2000, with thousands of article written by lawyers, law Students and Scholars on all branches of law\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\",\"name\":\"Legal Service India\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-circle-1.png\",\"contentUrl\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-circle-1.png\",\"width\":105,\"height\":95,\"caption\":\"Legal Service India\"},\"image\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/legalservicesind\",\"https:\\\/\\\/x.com\\\/legalserviceind\",\"https:\\\/\\\/www.youtube.com\\\/@LegalServiceIndia-lsi\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/person\\\/b2a982e671155e9713fde14405ffa316\",\"name\":\"Swatikumari022\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm\",\"url\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm\",\"contentUrl\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm\",\"caption\":\"Swatikumari022\"},\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/author\\\/swatikumari022\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Balancing Intellectual Property Rights And Access To Medicine - Legal Service India - Articles","description":"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Balancing Intellectual Property Rights And Access To Medicine","og_description":"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.","og_url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/","og_site_name":"Legal Service India - Articles","article_publisher":"https:\/\/www.facebook.com\/legalservicesind","article_published_time":"2026-06-14T05:01:14+00:00","article_modified_time":"2026-06-14T05:04:19+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","type":"image\/webp"}],"author":"Swatikumari022","twitter_card":"summary_large_image","twitter_creator":"@legalserviceind","twitter_site":"@legalserviceind","twitter_misc":{"Written by":"Swatikumari022","Est. reading time":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#article","isPartOf":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/"},"author":{"name":"Swatikumari022","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/person\/b2a982e671155e9713fde14405ffa316"},"headline":"Balancing Intellectual Property Rights And Access To Medicine","datePublished":"2026-06-14T05:01:14+00:00","dateModified":"2026-06-14T05:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/"},"wordCount":4059,"commentCount":0,"publisher":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization"},"image":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","keywords":["Intellectual Property"],"articleSection":["Intellectual Property"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/","name":"Balancing Intellectual Property Rights And Access To Medicine - Legal Service India - Articles","isPartOf":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","datePublished":"2026-06-14T05:01:14+00:00","dateModified":"2026-06-14T05:04:19+00:00","description":"Explore how pharmaceutical patents, TRIPS, generic medicines, and compulsory licensing shape global access to affordable healthcare.","breadcrumb":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#primaryimage","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","contentUrl":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","width":1536,"height":1024,"caption":"Intellectual Property Rights and Access to Medicines"},{"@type":"BreadcrumbList","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/balancing-intellectual-property-rights-and-access-to-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/"},{"@type":"ListItem","position":2,"name":"Intellectual Property > Balancing Intellectual Property Rights And Access To Medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#website","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/","name":"Legal Service India - Law Articles","description":"Legal Service India - Law Article Directory is the oldest in India since 2000, with thousands of article written by lawyers, law Students and Scholars on all branches of law","publisher":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization","name":"Legal Service India","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/logo\/image\/","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/06\/logo-circle-1.png","contentUrl":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/06\/logo-circle-1.png","width":105,"height":95,"caption":"Legal Service India"},"image":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/legalservicesind","https:\/\/x.com\/legalserviceind","https:\/\/www.youtube.com\/@LegalServiceIndia-lsi"]},{"@type":"Person","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/person\/b2a982e671155e9713fde14405ffa316","name":"Swatikumari022","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.gravatar.com\/avatar\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm","url":"\/\/www.gravatar.com\/avatar\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm","contentUrl":"\/\/www.gravatar.com\/avatar\/7e6351480a64e1a3f776206ff6eac33a?s=96&#038;r=g&#038;d=mm","caption":"Swatikumari022"},"url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/author\/swatikumari022\/"}]}},"jetpack_featured_media_url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2026\/06\/intellectual-property-rights-access-to-medicines-pharmaceutical-patents-generic-drugs.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/26074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/users\/1593"}],"replies":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/comments?post=26074"}],"version-history":[{"count":2,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/26074\/revisions"}],"predecessor-version":[{"id":26089,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/26074\/revisions\/26089"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media\/26088"}],"wp:attachment":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media?parent=26074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/categories?post=26074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/tags?post=26074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}